{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:15:54Z","timestamp":1794572154335,"version":"4.9.1"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novartis"},{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lilly"},{"name":"FWO Vlaanderen Fundamental Research scholarship"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a disabling and chronic neurovascular headache disorder. Trigeminal vascular activation and release of calcitonin gene-related peptide (CGRP) play a pivotal role in the pathogenesis of migraine. This knowledge has led to the development of CGRP(-receptor) therapies. Yet, a substantial proportion of patients do not respond to these treatments. Therefore, alternative targets for future therapies are warranted. The current narrative review provides a comprehensive overview of the pathophysiological role of these possible non-CGRP targets in migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>We covered targets of the metabotropic receptors (pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP), amylin, and adrenomedullin), intracellular targets (nitric oxide (NO), phosphodiesterase-3 (PDE3) and -5 (PDE5)), and ion channels (potassium, calcium, transient receptor potential (TRP), and acid-sensing ion channels (ASIC)). The majority of non-CGRP targets were able to induce migraine-like attacks, except for (i) calcium channels, as it is not yet possible to directly target channels to elucidate their precise involvement in migraine; (ii) TRP channels, activation of which can induce non-migraine headache; and (iii) ASICs, as their potential in inducing migraine attacks has not been investigated thus far.<\/jats:p>\n                    <jats:p>\n                      Drugs that target its receptors exist for PACAP, NO, and the potassium, TRP, and ASIC channels. No selective drugs exist for the other targets, however, some existing (migraine) treatments appear to indirectly antagonize responses to amylin, adrenomedullin, and calcium channels. Drugs against PACAP, NO, potassium channels, TRP channels, and only a PAC\n                      <jats:sub>1<\/jats:sub>\n                      antibody have been tested for migraine treatment, albeit with ambiguous results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While current research on these non-CGRP drug targets has not yet led to the development of efficacious therapies, human provocation studies using these targets have provided valuable insight into underlying mechanisms of migraine headaches and auras. Further studies are needed on these alternative therapies in non-responders of CGRP(-receptor) targeted therapies with the ultimate aim to pave the way towards a headache-free future for all migraine patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01567-4","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T19:02:22Z","timestamp":1687892542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Future targets for migraine treatment beyond CGRP"],"prefix":"10.1186","volume":"24","author":[{"given":"Linda","family":"Al-Hassany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre M.","family":"Boucherie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Creeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben W. A.","family":"van Drie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Farham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Favaretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Gollion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lou","family":"Grangeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Marschollek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Onan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Pensato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Stanyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Waliszewska-Pros\u00f3\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wietse","family":"Wiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Zhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"1567_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","DOI":"10.1177\/0333102417738202"},{"issue":"10258","key":"1567_CR2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204\u20131222","journal-title":"Lancet"},{"issue":"10283","key":"1567_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A et al (2021) Migraine: epidemiology and systems of care. Lancet 397(10283):1485\u20131495. https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7","journal-title":"Lancet"},{"issue":"9","key":"1567_CR4","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/0333102409355601","volume":"30","author":"TW Victor","year":"2010","unstructured":"Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB (2010) Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 30(9):1065\u20131072","journal-title":"Cephalalgia"},{"issue":"3","key":"1567_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/bph.15605","volume":"179","author":"TA Rees","year":"2022","unstructured":"Rees TA, Hendrikse ER, Hay DL, Walker CS (2022) Beyond CGRP: the calcitonin peptide family as targets for migraine and pain. Br J Pharmacol 179(3):381\u2013399","journal-title":"Br J Pharmacol"},{"issue":"10283","key":"1567_CR6","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MA, de Boer I, Lee MJ, Hay DL et al (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397(10283):1496\u20131504. https:\/\/doi.org\/10.1016\/S0140-6736(20)32162-0","journal-title":"Lancet"},{"issue":"6","key":"1567_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic. Nat Rev Neurol 14(6):338\u2013350","journal-title":"Nat Rev Neurol"},{"key":"1567_CR8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/s0140-6736(18)30478-1","volume":"391","author":"DW Dodick","year":"2018","unstructured":"Dodick DW (2018) Migraine. Lancet 391:1315\u20131330. https:\/\/doi.org\/10.1016\/s0140-6736(18)30478-1","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1567_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/head.13300","volume":"58","author":"DW Dodick","year":"2018","unstructured":"Dodick DW (2018) A phase-by-phase review of migraine pathophysiology. Headache 58(Suppl 1):4\u201316","journal-title":"Headache"},{"issue":"5","key":"1567_CR10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ana.20619","volume":"58","author":"D Levy","year":"2005","unstructured":"Levy D, Burstein R, Strassman AM (2005) Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58(5):698\u2013705","journal-title":"Ann Neurol"},{"issue":"10283","key":"1567_CR11","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ et al (2021) Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397(10283):1505\u20131518. https:\/\/doi.org\/10.1016\/S0140-6736(20)32342-4","journal-title":"Lancet"},{"issue":"3","key":"1567_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284\u2013294","journal-title":"Lancet Neurol"},{"issue":"6","key":"1567_CR13","first-page":"1656","volume":"11","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Villar-Mart\u00ednez MD, Goadsby PJ (2022) New generation gepants: migraine acute and preventive medications. J Clin Med Res 11(6):1656","journal-title":"J Clin Med Res"},{"key":"1567_CR14","doi-asserted-by":"publisher","first-page":"649143","DOI":"10.3389\/fphar.2021.649143","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Chen Y, Song J, You C (2021) Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. Front Pharmacol 12:649143","journal-title":"Front Pharmacol"},{"issue":"7","key":"1567_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.neurol.2021.06.005","volume":"177","author":"TP Do","year":"2021","unstructured":"Do TP, Al-Saoudi A, Ashina M (2021) Future prophylactic treatments in migraine: beyond anti-CGRP monoclonal antibodies and gepants. Rev Neurol 177(7):827\u2013833","journal-title":"Rev Neurol"},{"issue":"2","key":"1567_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","volume":"17","author":"A Charles","year":"2018","unstructured":"Charles A (2018) The pathophysiology of migraine: implications for clinical management. Lancet Neurol 17(2):174\u2013182","journal-title":"Lancet Neurol"},{"issue":"1","key":"1567_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","volume":"164","author":"A Miyata","year":"1989","unstructured":"Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L et al (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164(1):567\u2013574","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1567_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.nurt.2010.02.003","volume":"7","author":"HW Schytz","year":"2010","unstructured":"Schytz HW, Olesen J, Ashina M (2010) The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics 7(2):191\u2013196","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1567_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1476-5381.2012.01871.x","volume":"166","author":"AJ Harmar","year":"2012","unstructured":"Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR et al (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166(1):4\u201317","journal-title":"Br J Pharmacol"},{"issue":"Pt 3","key":"1567_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/brain\/awt369","volume":"137","author":"FM Amin","year":"2014","unstructured":"Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI et al (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 137(Pt 3):779\u2013794","journal-title":"Brain"},{"issue":"2","key":"1567_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/MED.0000000000000717","volume":"29","author":"R Dominguez-Moreno","year":"2022","unstructured":"Dominguez-Moreno R, Do TP, Ashina M (2022) Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment. Curr Opin Endocrinol Diabetes Obes 29(2):225\u2013231","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1567_CR22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fphys.2018.01249","volume":"9","author":"Z Kee","year":"2018","unstructured":"Kee Z, Kodji X, Brain SD (2018) The role of Calcitonin Gene Related Peptide (CGRP) in neurogenic vasodilation and its cardioprotective effects. Front Physiol 9:1249","journal-title":"Front Physiol"},{"issue":"2","key":"1567_CR23","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103(2):1565\u20131644","journal-title":"Physiol Rev"},{"issue":"2\u20133","key":"1567_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0167-0115(85)90013-8","volume":"10","author":"ME Kraenzlin","year":"1985","unstructured":"Kraenzlin ME, Ch\u2019ng JL, Mulderry PK, Ghatei MA, Bloom SR (1985) Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. Regul Pept 10(2\u20133):189\u2013197","journal-title":"Regul Pept"},{"issue":"6","key":"1567_CR25","first-page":"619","volume":"21","author":"NM Sherwood","year":"2000","unstructured":"Sherwood NM, Krueckl SL, McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)\/glucagon superfamily. Endocr Rev 21(6):619\u2013670","journal-title":"Endocr Rev"},{"issue":"1","key":"1567_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s10194-018-0855-1","volume":"19","author":"T Hirabayashi","year":"2018","unstructured":"Hirabayashi T, Nakamachi T, Shioda S (2018) Discovery of PACAP and its receptors in the brain. J Headache Pain 19(1):28","journal-title":"J Headache Pain"},{"key":"1567_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.peptides.2015.01.009","volume":"66","author":"I Ramos-\u00c1lvarez","year":"2015","unstructured":"Ramos-\u00c1lvarez I, Mantey SA, Nakamura T, Nuche-Berenguer B, Moreno P, Moody TW et al (2015) A structure\u2013function study of PACAP using conformationally restricted analogs: identification of PAC1 receptor-selective PACAP agonists. Peptides 66:26\u201342","journal-title":"Peptides"},{"issue":"6","key":"1567_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.peptides.2008.01.022","volume":"29","author":"S Bourgault","year":"2008","unstructured":"Bourgault S, Vaudry D, Botia B, Couvineau A, Laburthe M, Vaudry H et al (2008) Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 29(6):919\u2013932","journal-title":"Peptides"},{"issue":"2","key":"1567_CR29","first-page":"690","volume":"267","author":"WA Banks","year":"1993","unstructured":"Banks WA, Kastin AJ, Komaki G, Arimura A (1993) Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 267(2):690\u2013696","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1567_CR30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/apha.12427","volume":"213","author":"D Ganea","year":"2015","unstructured":"Ganea D, Hooper KM, Kong W (2015) The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol 213(2):442\u2013452","journal-title":"Acta Physiol"},{"issue":"1","key":"1567_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-017-0822-2","volume":"19","author":"I Jansen-Olesen","year":"2018","unstructured":"Jansen-Olesen I, Hougaard PS (2018) PACAP and its receptors in cranial arteries and mast cells. J Headache Pain 19(1):16","journal-title":"J Headache Pain"},{"issue":"11","key":"1567_CR32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gut.19.11.1049","volume":"19","author":"S Domschke","year":"1978","unstructured":"Domschke S, Domschke W, Bloom SR, Mitznegg P, Mitchell SJ, Lux G et al (1978) Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 19(11):1049\u20131053","journal-title":"Gut"},{"issue":"3","key":"1567_CR33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0196-9781(03)00059-7","volume":"24","author":"D Dogrukol-Ak","year":"2003","unstructured":"Dogrukol-Ak D, Banks WA, Tuncel N, Tuncel M (2003) Passage of vasoactive intestinal peptide across the blood\u2013brain barrier. Peptides 24(3):437\u2013444","journal-title":"Peptides"},{"issue":"3","key":"1567_CR34","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/pr.115.010629","volume":"67","author":"DL Hay","year":"2015","unstructured":"Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD (2015) Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev 67(3):564\u2013600","journal-title":"Pharmacol Rev"},{"issue":"5","key":"1567_CR35","first-page":"E903","volume":"274","author":"M Clodi","year":"1998","unstructured":"Clodi M, Thomaseth K, Pacini G, Hermann K, Kautzky-Willer A, Waldh\u00fcsl W et al (1998) Distribution and kinetics of amylin in humans. Am J Physiol 274(5):E903\u2013E908","journal-title":"Am J Physiol"},{"issue":"22","key":"1567_CR36","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/0024-3205(95)02197-Q","volume":"57","author":"WA Banks","year":"1995","unstructured":"Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB (1995) Permeability of the blood-brain barrier to amylin. Life Sci 57(22):1993\u20132001","journal-title":"Life Sci"},{"issue":"6","key":"1567_CR37","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s12031-020-01493-z","volume":"70","author":"L Edvinsson","year":"2020","unstructured":"Edvinsson L, Grell AS, Warfvinge K (2020) Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. J Mol Neurosci 70(6):930\u2013944","journal-title":"J Mol Neurosci"},{"issue":"4","key":"1567_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1365-2826.2002.00778.x","volume":"14","author":"B Kis","year":"2002","unstructured":"Kis B, Kaiya H, Nishi R, Deli MA, Abrah\u00e1m CS, Yanagita T et al (2002) Cerebral endothelial cells are a major source of adrenomedullin. J Neuroendocrinol 14(4):283\u2013293","journal-title":"J Neuroendocrinol"},{"issue":"43","key":"1567_CR39","doi-asserted-by":"publisher","first-page":"16027","DOI":"10.1073\/pnas.0602488103","volume":"103","author":"W Ma","year":"2006","unstructured":"Ma W, Chabot JG, Quirion R (2006) A role for adrenomedullin as a pain-related peptide in the rat. Proc Natl Acad Sci U S A 103(43):16027\u201316032","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1567_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/bph.15628","volume":"179","author":"ML Garelja","year":"2022","unstructured":"Garelja ML, Bower RL, Brimble MA, Chand S, Harris PWR, Jamaluddin MA et al (2022) Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors. Br J Pharmacol 179(3):416\u2013434","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1567_CR41","first-page":"95","volume":"82","author":"K Meeran","year":"1997","unstructured":"Meeran K, O\u2019Shea D, Upton PD, Small CJ, Ghatei MA, Byfield PH et al (1997) Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 82(1):95\u2013100","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"1567_CR42","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1097\/00001756-200112210-00055","volume":"12","author":"B Kis","year":"2001","unstructured":"Kis B, Deli MA, Kobayashi H, Abrah\u00e1m CS, Yanagita T, Kaiya H et al (2001) Adrenomedullin regulates blood-brain barrier functions in vitro. NeuroReport 12(18):4139\u20134142","journal-title":"NeuroReport"},{"issue":"6","key":"1567_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/10715769900301161","volume":"31","author":"DS Bredt","year":"1999","unstructured":"Bredt DS (1999) Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 31(6):577\u2013596","journal-title":"Free Radic Res"},{"issue":"2","key":"1567_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pneurobio.2005.06.001","volume":"76","author":"FX Guix","year":"2005","unstructured":"Guix FX, Uribesalgo I, Coma M, Mu\u00f1oz FJ (2005) The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 76(2):126\u2013152","journal-title":"Prog Neurobiol"},{"issue":"1","key":"1567_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1073\/pnas.98.1.355","volume":"98","author":"DD Thomas","year":"2001","unstructured":"Thomas DD, Liu X, Kantrow SP, Lancaster JR (2001) The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proc Natl Acad Sci U S A 98(1):355\u2013360","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1567_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.pharmthera.2008.08.003","volume":"120","author":"J Olesen","year":"2008","unstructured":"Olesen J (2008) The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 120(2):157\u2013171","journal-title":"Pharmacol Ther"},{"issue":"7","key":"1567_CR47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/0333102413515345","volume":"34","author":"JC Nordgaard","year":"2014","unstructured":"Nordgaard JC, Kruse LS, M\u00f8ller M, Kruuse C (2014) Phosphodiesterases 3 and 5 express activity in the trigeminal ganglion and co-localize with calcitonin gene-related peptide. Cephalalgia 34(7):503\u2013513","journal-title":"Cephalalgia"},{"issue":"3","key":"1567_CR48","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"AT Bender","year":"2006","unstructured":"Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58(3):488\u2013520","journal-title":"Pharmacol Rev"},{"issue":"8","key":"1567_CR49","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd2058","volume":"5","author":"FS Menniti","year":"2006","unstructured":"Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5(8):660\u2013670","journal-title":"Nat Rev Drug Discov"},{"key":"1567_CR50","doi-asserted-by":"publisher","first-page":"111311","DOI":"10.1016\/j.mad.2020.111311","volume":"190","author":"V Cesarini","year":"2020","unstructured":"Cesarini V, Guida E, Campolo F, Crescioli C, Di Baldassarre A, Pisano C et al (2020) Type 5 phosphodiesterase (PDE5) and the vascular tree: from embryogenesis to aging and disease. Mech Ageing Dev 190:111311","journal-title":"Mech Ageing Dev"},{"issue":"1","key":"1567_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.taap.2004.03.019","volume":"200","author":"LK Pershing","year":"2004","unstructured":"Pershing LK, Reilly CA, Corlett JL, Crouch DJ (2004) Effects of vehicle on the uptake and elimination kinetics of capsaicinoids in human skin in vivo. Toxicol Appl Pharmacol 200(1):73\u201381","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"1567_CR52","first-page":"108","volume":"92","author":"K Chaiyasit","year":"2009","unstructured":"Chaiyasit K, Khovidhunkit W, Wittayalertpanya S (2009) Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. J Med Assoc Thai 92(1):108\u2013113","journal-title":"J Med Assoc Thai"},{"key":"1567_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0021-9673(01)81899-9","volume":"329","author":"T Kawada","year":"1985","unstructured":"Kawada T, Watanabe T, Katsura K, Takami H, Iwai K (1985) Formation and metabolism of pungent principle of capsicum fruits: XV. Microdetermination of capsaicin by high-performance liquid chromatography with electrochemical detection. J Chromatogr A 329:99\u2013105","journal-title":"J Chromatogr A"},{"key":"1567_CR54","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jconrel.2014.09.027","volume":"196","author":"WD Rollyson","year":"2014","unstructured":"Rollyson WD, Stover CA, Brown KC, Perry HE, Stevenson CD, McNees CA et al (2014) Bioavailability of capsaicin and its implications for drug delivery. J Control Release 196:96\u2013105","journal-title":"J Control Release"},{"issue":"4","key":"1567_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.2042-7158.1982.tb04245.x","volume":"34","author":"A Saria","year":"1982","unstructured":"Saria A, Skofitsch G, Lembeck F (1982) Distribution of capsaicin in rat tissues after systemic administration. J Pharm Pharmacol 34(4):273\u2013275","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"1567_CR56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF02976541","volume":"22","author":"YS Kang","year":"1999","unstructured":"Kang YS, Kim JM (1999) Permeability of a capsaicin derivative, [14C]DA-5018 to blood-brain barrier corrected with HPLC method. Arch Pharm Res 22(2):165\u2013172","journal-title":"Arch Pharm Res"},{"issue":"Pt 1","key":"1567_CR57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/brain\/awn307","volume":"132","author":"HW Schytz","year":"2009","unstructured":"Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132(Pt 1):16\u201325","journal-title":"Brain"},{"issue":"2","key":"1567_CR58","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/0333102411431333","volume":"32","author":"FM Amin","year":"2012","unstructured":"Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW et al (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 32(2):140\u2013149","journal-title":"Cephalalgia"},{"key":"1567_CR59","doi-asserted-by":"publisher","first-page":"170134","DOI":"10.1016\/j.peptides.2019.170134","volume":"121","author":"H Ghanizada","year":"2019","unstructured":"Ghanizada H, Al-Karagholi MAM, Arngrim N, Ghanizada M, Larsson HBW, Amin FM et al (2019) Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study. Peptides 121:170134","journal-title":"Peptides"},{"issue":"1","key":"1567_CR60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0333102419864507","volume":"40","author":"H Ghanizada","year":"2020","unstructured":"Ghanizada H, Al-Karagholi MAM, Arngrim N, Olesen J, Ashina M (2020) PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia 40(1):57\u201367","journal-title":"Cephalalgia"},{"issue":"1","key":"1567_CR61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-018-0861-3","volume":"19","author":"FM Amin","year":"2018","unstructured":"Amin FM, Schytz HW (2018) Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine. J Headache Pain 19(1):35","journal-title":"J Headache Pain"},{"issue":"3","key":"1567_CR62","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0333102412468340","volume":"33","author":"G Gr\u00e4nde","year":"2013","unstructured":"Gr\u00e4nde G, Nilsson E, Edvinsson L (2013) Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myography and pressurized cerebral artery method. Cephalalgia 33(3):152\u2013159","journal-title":"Cephalalgia"},{"issue":"3","key":"1567_CR63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.regpep.2006.12.010","volume":"140","author":"S Birk","year":"2007","unstructured":"Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J et al (2007) The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 140(3):185\u2013191","journal-title":"Regul Pept"},{"issue":"9","key":"1567_CR64","first-page":"1044","volume":"44","author":"T Mori","year":"1994","unstructured":"Mori T, Kawashima T, Beppu Y, Takagi K (1994) Histamine release induced by pituitary adenylate cyclase activating polypeptide from rat peritoneal mast cells. Arzneimittelforschung 44(9):1044\u20131046","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"1567_CR65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0304-3959(88)90012-7","volume":"8","author":"AA Krabbe","year":"1980","unstructured":"Krabbe AA, Olesen J (1980) Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms. Pain 8(2):253\u2013259","journal-title":"Pain"},{"issue":"5","key":"1567_CR66","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0333102418798611","volume":"39","author":"LH Vollesen","year":"2019","unstructured":"Vollesen LH, Guo S, Andersen MR, Ashina M (2019) Effect of the H1-antihistamine clemastine on PACAP38 induced migraine. Cephalalgia 39(5):597\u2013607","journal-title":"Cephalalgia"},{"issue":"6","key":"1567_CR67","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1177\/0333102420975395","volume":"41","author":"NKF Wienholtz","year":"2021","unstructured":"Wienholtz NKF, Christensen CE, Zhang DG, Coskun H, Ghanizada H, Al-Karagholi MAM et al (2021) Early treatment with sumatriptan prevents PACAP38-induced migraine: a randomised clinical trial. Cephalalgia 41(6):731\u2013748","journal-title":"Cephalalgia"},{"issue":"2","key":"1567_CR68","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s13311-017-0596-x","volume":"15","author":"ALH Vollesen","year":"2018","unstructured":"Vollesen ALH, Amin FM, Ashina M (2018) Targeted pituitary adenylate cyclase-activating peptide therapies for migraine. Neurotherapeutics 15(2):371\u2013376","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1567_CR69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0333102420970889","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Dole\u017eil D, Bonner JH, Zhou L, Klatt J, Picard H et al (2021) A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 41(1):33\u201344","journal-title":"Cephalalgia"},{"issue":"1","key":"1567_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-018-0852-4","volume":"19","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Tajti J, Szal\u00e1rdy L, V\u00e9csei L (2018) PACAP and its role in primary headaches. J Headache Pain 19(1):21","journal-title":"J Headache Pain"},{"key":"1567_CR71","doi-asserted-by":"publisher","first-page":"105946","DOI":"10.1016\/j.nbd.2022.105946","volume":"176","author":"S Guo","year":"2023","unstructured":"Guo S, Jansen-Olesen I, Olesen J, Christensen SL (2023) Role of PACAP in migraine: an alternative to CGRP? Neurobiol Dis 176:105946","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1567_CR72","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s10194-018-0893-8","volume":"19","author":"E Rubio-Beltr\u00e1n","year":"2018","unstructured":"Rubio-Beltr\u00e1n E, Correnti E, Deen M, Kamm K, Kelderman T, Papetti L et al (2018) PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain 19(1):64","journal-title":"J Headache Pain"},{"issue":"5","key":"1567_CR73","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2174\/187152710793361595","volume":"9","author":"CM White","year":"2010","unstructured":"White CM, Ji S, Cai H, Maudsley S, Martin B (2010) Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS Neurol Disord Drug Targets 9(5):661\u2013666","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"1567_CR74","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1134\/S1819712422010123","volume":"16","author":"AY Sokolov","year":"2022","unstructured":"Sokolov AY, Osipchuk AV, Skiba IB, Amelin AV (2022) The role of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in migraine pathogenesis. Neurochem J 16(1):31\u201338","journal-title":"Neurochem J"},{"issue":"4","key":"1567_CR75","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/0333102414535111","volume":"35","author":"E Cernuda-Moroll\u00f3n","year":"2015","unstructured":"Cernuda-Moroll\u00f3n E, Mart\u00ednez-Camblor P, Alvarez R, Larrosa D, Ram\u00f3n C, Pascual J (2015) Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia 35(4):310\u2013316","journal-title":"Cephalalgia"},{"key":"1567_CR76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.npep.2015.03.006","volume":"52","author":"J Tajti","year":"2015","unstructured":"Tajti J, Szok D, Majl\u00e1th Z, Tuka B, Cs\u00e1ti A, V\u00e9csei L (2015) Migraine and neuropeptides. Neuropeptides 52:19\u201330","journal-title":"Neuropeptides"},{"issue":"8","key":"1567_CR77","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/j.1468-2982.2006.01149.x","volume":"26","author":"JM Hansen","year":"2006","unstructured":"Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J et al (2006) Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 26(8):992\u20131003","journal-title":"Cephalalgia"},{"issue":"11","key":"1567_CR78","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1177\/0333102420937655","volume":"40","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, Al-Karagholi MAM, Chaudhry BA, Lopez CL, Snellman J, Hannibal J et al (2020) Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia 40(11):1212\u20131223","journal-title":"Cephalalgia"},{"issue":"3","key":"1567_CR79","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1468-2982.2007.01497.x","volume":"28","author":"A Rahmann","year":"2008","unstructured":"Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28(3):226\u2013236","journal-title":"Cephalalgia"},{"issue":"8","key":"1567_CR80","doi-asserted-by":"publisher","first-page":"e2118543","DOI":"10.1001\/jamanetworkopen.2021.18543","volume":"4","author":"L Pellesi","year":"2021","unstructured":"Pellesi L, Al-Karagholi MAM, De Icco R, Coskun H, Elbahi FA, Lopez-Lopez C et al (2021) Effect of vasoactive intestinal polypeptide on development of migraine headaches. JAMA Netw Open 4(8):e2118543","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1567_CR81","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/archneurpsyc.1938.02270040093005","volume":"39","author":"JR Graham","year":"1938","unstructured":"Graham JR, Wolff HG (1938) Mechanism of migraine headache and action of ergotamine tartrate. Arch NeurPsych 39(4):737\u2013763","journal-title":"Arch NeurPsych"},{"issue":"7","key":"1567_CR82","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S1474-4422(09)70090-0","volume":"8","author":"J Olesen","year":"2009","unstructured":"Olesen J, Burstein R, Ashina M, Tfelt-Hansen P (2009) Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 8(7):679\u2013690","journal-title":"Lancet Neurol"},{"issue":"Suppl 2","key":"1567_CR83","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/head.13077","volume":"57","author":"DL Hay","year":"2017","unstructured":"Hay DL (2017) Amylin. Headache 57(Suppl 2):89\u201396","journal-title":"Headache"},{"issue":"6","key":"1567_CR84","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1210\/endo.137.6.8641217","volume":"137","author":"A Mart\u00ednez","year":"1996","unstructured":"Mart\u00ednez A, Weaver C, L\u00f3pez J, Bhathena SJ, Elsasser TH, Miller MJ et al (1996) Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology 137(6):2626\u20132632","journal-title":"Endocrinology"},{"issue":"1 Suppl","key":"1567_CR85","doi-asserted-by":"publisher","first-page":"47S","DOI":"10.1177\/0145721715607642","volume":"41","author":"L Hieronymus","year":"2015","unstructured":"Hieronymus L, Griffin S (2015) Role of amylin in Type 1 and Type 2 diabetes. Diabetes Educ 41(1 Suppl):47S-56S","journal-title":"Diabetes Educ"},{"issue":"10","key":"1567_CR86","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.clinthera.2005.10.009","volume":"27","author":"GJ Ryan","year":"2005","unstructured":"Ryan GJ, Jobe LJ, Martin R (2005) Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 27(10):1500\u20131512","journal-title":"Clin Ther"},{"issue":"9","key":"1567_CR87","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.metabol.2004.04.010","volume":"53","author":"T Heise","year":"2004","unstructured":"Heise T, Heinemann L, Heller S, Weyer C, Wang Y, Strobel S et al (2004) Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism 53(9):1227\u20131232","journal-title":"Metabolism"},{"issue":"6","key":"1567_CR88","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/ana.26072","volume":"89","author":"H Ghanizada","year":"2021","unstructured":"Ghanizada H, Al-Karagholi MAM, Walker CS, Arngrim N, Rees T, Petersen J et al (2021) Amylin analog pramlintide induces migraine-like attacks in patients. Ann Neurol 89(6):1157\u20131171","journal-title":"Ann Neurol"},{"issue":"5","key":"1567_CR89","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0333102420977106","volume":"41","author":"P Irimia","year":"2021","unstructured":"Irimia P, Mart\u00ednez-Valbuena I, M\u00ednguez-Olaondo A, Dom\u00ednguez-Vivero C, S\u00e1nchez-Arias JA, Mart\u00ednez-Vila E et al (2021) Interictal amylin levels in chronic migraine patients: a case-control study. Cephalalgia 41(5):604\u2013612","journal-title":"Cephalalgia"},{"issue":"11","key":"1567_CR90","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3389\/fphar.2020.01240","volume":"20","author":"KS Pan","year":"2020","unstructured":"Pan KS, Siow A, Hay DL, Walker CS (2020) Antagonism of CGRP signaling by Rimegepant at two receptors. Front Pharmacol 20(11):1240","journal-title":"Front Pharmacol"},{"key":"1567_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-022-01425-9","volume":"23","author":"SHL Cour","year":"2022","unstructured":"Cour SHL, La Cour SH, Juhler K, Kogelman LJA, Olesen J, Kl\u00e6rke DA et al (2022) Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor. J Headache Pain 23:59","journal-title":"J Headache Pain"},{"issue":"3","key":"1567_CR92","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/bph.15585","volume":"179","author":"ML Garelja","year":"2022","unstructured":"Garelja ML, Walker CS, Hay DL (2022) CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists? Br J Pharmacol 179(3):454\u2013459","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1567_CR93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bph.14075","volume":"175","author":"DL Hay","year":"2018","unstructured":"Hay DL, Garelja ML, Poyner DR, Walker CS (2018) Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol 175(1):3\u201317","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1567_CR94","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1210\/me.2006-0156","volume":"21","author":"C Gibbons","year":"2007","unstructured":"Gibbons C, Dackor R, Dunworth W, Fritz-Six K, Caron KM (2007) Receptor activity-modifying proteins: RAMPing up adrenomedullin signaling. Mol Endocrinol 21(4):783\u2013796","journal-title":"Mol Endocrinol"},{"issue":"7","key":"1567_CR95","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/bph.12129","volume":"170","author":"CS Walker","year":"2013","unstructured":"Walker CS, Hay DL (2013) CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol 170(7):1293\u20131307","journal-title":"Br J Pharmacol"},{"issue":"7\u20138","key":"1567_CR96","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/psc.2953","volume":"23","author":"R Sch\u00f6nauer","year":"2017","unstructured":"Sch\u00f6nauer R, Els-Heindl S (2017) Adrenomedullin\u2013new perspectives of a potent peptide hormone. J Pept Sci 23(7\u20138):472\u2013485","journal-title":"J Pept Sci"},{"issue":"5","key":"1567_CR97","first-page":"cvd.2012.012003","volume":"1","author":"HK Wong","year":"2012","unstructured":"Wong HK, Cheung TT, Cheung BMY (2012) Adrenomedullin and cardiovascular diseases. JRSM Cardiovasc Dis 1(5):cvd.2012.012003","journal-title":"JRSM Cardiovasc Dis"},{"issue":"690","key":"1567_CR98","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neulet.2018.10.037","volume":"18","author":"H Huang","year":"2019","unstructured":"Huang H, Wang M, Hong Y (2019) Intrathecal administration of adrenomedullin induces mechanical allodynia and neurochemical changes in spinal cord and DRG. Neurosci Lett 18(690):196\u2013201","journal-title":"Neurosci Lett"},{"issue":"20","key":"1567_CR99","doi-asserted-by":"publisher","first-page":"e2488","DOI":"10.1212\/WNL.0000000000011930","volume":"96","author":"H Ghanizada","year":"2021","unstructured":"Ghanizada H, Al-Karagholi MAM, Arngrim N, M\u00f8rch-Rasmussen M, Walker CS, Hay DL et al (2021) Effect of adrenomedullin on migraine-like attacks in patients with migraine: a randomized crossover study. Neurology 96(20):e2488\u2013e2499","journal-title":"Neurology"},{"issue":"1","key":"1567_CR100","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1468-2982.2008.01695.x","volume":"29","author":"KA Petersen","year":"2009","unstructured":"Petersen KA, Birk S, Kitamura K, Olesen J (2009) Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia 29(1):23\u201330","journal-title":"Cephalalgia"},{"issue":"4","key":"1567_CR101","doi-asserted-by":"publisher","first-page":"153","DOI":"10.17546\/msd.08866","volume":"3","author":"A Akcali","year":"2016","unstructured":"Akcali A, Geyik S, Dogru I, Dogru A, Yurekli M, Neyal A et al (2016) Plasma adrenomedullin levels in patients with migraine during naturel attack and attack free period. Med Sci Discov 3(4):153\u2013158","journal-title":"Med Sci Discov"},{"issue":"3","key":"1567_CR102","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1152\/physrev.00037.2003","volume":"84","author":"SD Brain","year":"2004","unstructured":"Brain SD, Grant AD (2004) Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84(3):903\u2013934","journal-title":"Physiol Rev"},{"issue":"2","key":"1567_CR103","first-page":"138","volume":"21","author":"JP Hinson","year":"2000","unstructured":"Hinson JP, Kapas S, Smith DM (2000) Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 21(2):138\u2013167","journal-title":"Endocr Rev"},{"issue":"5","key":"1567_CR104","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/0333102420983282","volume":"41","author":"M Bhakta","year":"2021","unstructured":"Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD (2021) Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia 41(5):499\u2013514","journal-title":"Cephalalgia"},{"issue":"1","key":"1567_CR105","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s10194-022-01464-2","volume":"23","author":"H Ashina","year":"2022","unstructured":"Ashina H, Christensen RH, Ashina M (2022) Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences. J Headache Pain 23(1):87","journal-title":"J Headache Pain"},{"issue":"19","key":"1567_CR106","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383(19):1866\u20131876","journal-title":"N Engl J Med"},{"issue":"12","key":"1567_CR107","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrneurol.2017.137","volume":"13","author":"M Ashina","year":"2017","unstructured":"Ashina M, Hansen JM, Olesen J (2017) Human models of migraine\u2014short-term pain for long-term gain. Nat Rev Neurol 13(12):713\u2013724","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1567_CR108","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1046\/j.1468-1331.2000.00094.x","volume":"7","author":"I Christiansen","year":"2000","unstructured":"Christiansen I, Daugaard D, Lykke Thomsen L, Olesen J (2000) Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency. Eur J Neurol 7(4):405\u2013411","journal-title":"Eur J Neurol"},{"issue":"8","key":"1567_CR109","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1177\/0333102417737778","volume":"38","author":"M Ben Aissa","year":"2018","unstructured":"Ben Aissa M, Tipton AF, Bertels Z, Gandhi R, Moye LS, Novack M et al (2018) Soluble guanylyl cyclase is a critical regulator of migraine-associated pain. Cephalalgia 38(8):1471\u20131484","journal-title":"Cephalalgia"},{"issue":"1","key":"1567_CR110","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1468-2982.1998.1801027.x","volume":"18","author":"LH Lassen","year":"1998","unstructured":"Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J et al (1998) Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 18(1):27\u201332","journal-title":"Cephalalgia"},{"issue":"9","key":"1567_CR111","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/j.1468-2982.2006.01164.x","volume":"26","author":"P Sarchielli","year":"2006","unstructured":"Sarchielli P, Floridi A, Mancini ML, Rossi C, Coppola F, Baldi A et al (2006) NF-kappaB activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks. Cephalalgia 26(9):1071\u20131079","journal-title":"Cephalalgia"},{"issue":"1","key":"1567_CR112","first-page":"124","volume":"29","author":"JE Palmer","year":"2009","unstructured":"Palmer JE, Guillard FL, Laurijssens BE, Wentz AL (2009) A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 29(1):124","journal-title":"Cephalalgia"},{"issue":"12","key":"1567_CR113","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1177\/0333102410370875","volume":"30","author":"HO H\u00f8ivik","year":"2010","unstructured":"H\u00f8ivik HO, Laurijssens BE, Harnisch LO, Twomey CK, Dixon RM, Kirkham AJT et al (2010) Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30(12):1458\u20131467","journal-title":"Cephalalgia"},{"issue":"2","key":"1567_CR114","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/0333102412466967","volume":"33","author":"DK Bhatt","year":"2013","unstructured":"Bhatt DK, Gupta S, Jansen-Olesen I, Andrews JS, Olesen J (2013) NXN-188, a selective nNOS inhibitor and a 5-HT1B\/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia 33(2):87\u2013100","journal-title":"Cephalalgia"},{"issue":"1","key":"1567_CR115","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.sjpain.2012.08.002","volume":"4","author":"A Hougaard","year":"2013","unstructured":"Hougaard A, Hauge AW, Guo S, Tfelt-Hansen P (2013) The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study. Scand J Pain 4(1):48\u201352","journal-title":"Scand J Pain"},{"issue":"Pt 11","key":"1567_CR116","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1093\/brain\/awu244","volume":"137","author":"S Guo","year":"2014","unstructured":"Guo S, Olesen J, Ashina M (2014) Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain 137(Pt 11):2951\u20132959","journal-title":"Brain"},{"issue":"1\u20132","key":"1567_CR117","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neulet.2006.05.045","volume":"404","author":"LS Kruse","year":"2006","unstructured":"Kruse LS, Sandholdt NTH, Gammeltoft S, Olesen J, Kruuse C (2006) Phosphodiesterase 3 and 5 and cyclic nucleotide-gated ion channel expression in rat trigeminovascular system. Neurosci Lett 404(1\u20132):202\u2013207","journal-title":"Neurosci Lett"},{"issue":"1","key":"1567_CR118","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s10194-018-0841-7","volume":"19","author":"K Falkenberg","year":"2018","unstructured":"Falkenberg K, Dunga B\u00d3\u00c1, Guo S, Ashina M, Olesen J (2018) Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. J Headache Pain 19(1):11","journal-title":"J Headache Pain"},{"issue":"Pt 1","key":"1567_CR119","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1113\/jphysiol.1996.sp021292","volume":"492","author":"SL Ingram","year":"1996","unstructured":"Ingram SL, Williams JT (1996) Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons. J Physiol 492(Pt 1):97\u2013106","journal-title":"J Physiol"},{"issue":"5","key":"1567_CR120","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0333102417719753","volume":"38","author":"S Khan","year":"2018","unstructured":"Khan S, Deen M, Hougaard A, Amin FM, Ashina M (2018) Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol. Cephalalgia 38(5):892\u2013903","journal-title":"Cephalalgia"},{"issue":"11","key":"1567_CR121","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1468-2982.2006.01218.x","volume":"26","author":"S Birk","year":"2006","unstructured":"Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J (2006) The headache-inducing effect of cilostazol in human volunteers. Cephalalgia 26(11):1304\u20131309","journal-title":"Cephalalgia"},{"issue":"4","key":"1567_CR122","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1389450033491046","volume":"4","author":"S Chrissobolis","year":"2003","unstructured":"Chrissobolis S, Sobey CG (2003) Inwardly rectifying potassium channels in the regulation of vascular tone. Curr Drug Targets 4(4):281\u2013289","journal-title":"Curr Drug Targets"},{"issue":"14","key":"1567_CR123","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1177\/03331024211038884","volume":"41","author":"SL Christensen","year":"2021","unstructured":"Christensen SL, Rasmussen RH, Ernstsen C, La Cour S, David A, Chaker J et al (2021) CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine. Cephalalgia 41(14):1413\u20131426","journal-title":"Cephalalgia"},{"issue":"12","key":"1567_CR124","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/01.WCB.0000143536.22131.D7","volume":"24","author":"S Birk","year":"2004","unstructured":"Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J (2004) The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24(12):1352\u20131358","journal-title":"J Cereb Blood Flow Metab"},{"issue":"8","key":"1567_CR125","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/0333102420915166","volume":"40","author":"K Falkenberg","year":"2020","unstructured":"Falkenberg K, Bjerg HR, Olesen J (2020) Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients. Cephalalgia 40(8):842\u2013850","journal-title":"Cephalalgia"},{"issue":"10","key":"1567_CR126","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/brain\/awy228","volume":"141","author":"JH Butt","year":"2018","unstructured":"Butt JH, Rostrup E, Hansen AS, Lambertsen KL, Kruuse C (2018) Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura. Brain 141(10):2943\u20132951","journal-title":"Brain"},{"issue":"9","key":"1567_CR127","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1526-4610.2004.04177.x","volume":"44","author":"RW Evans","year":"2004","unstructured":"Evans RW, Kruuse C (2004) Phosphodiesterase-5 inhibitors and migraine. Headache 44(9):925\u2013926","journal-title":"Headache"},{"issue":"20","key":"1567_CR128","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","volume":"338","author":"I Goldstein","year":"1998","unstructured":"Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338(20):1397\u20131404","journal-title":"N Engl J Med"},{"issue":"1","key":"1567_CR129","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/brain\/awg009","volume":"126","author":"C Kruuse","year":"2003","unstructured":"Kruuse C, Thomsen LL, Birk S, Olesen J (2003) Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126(1):241\u2013247","journal-title":"Brain"},{"issue":"9","key":"1567_CR130","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/00004647-200209000-00010","volume":"22","author":"C Kruuse","year":"2002","unstructured":"Kruuse C, Thomsen LL, Jacobsen TB, Olesen J (2002) The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab 22(9):1124\u20131131","journal-title":"J Cereb Blood Flow Metab"},{"issue":"14","key":"1567_CR131","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1177\/0333102419882474","volume":"39","author":"S Younis","year":"2019","unstructured":"Younis S, Christensen CE, Toft NM, S\u00f8borg T, Amin FM, Hougaard A et al (2019) Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil. Cephalalgia 39(14):1776\u20131788","journal-title":"Cephalalgia"},{"issue":"6","key":"1567_CR132","doi-asserted-by":"publisher","first-page":"L1004","DOI":"10.1152\/ajplung.00295.2002","volume":"284","author":"SA Barman","year":"2003","unstructured":"Barman SA, Zhu S, Han G, White RE (2003) cAMP activates BKCa channels in pulmonary arterial smooth muscle via cGMP-dependent protein kinase. Am J Physiol Lung Cell Mol Physiol 284(6):L1004\u2013L1011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"1567_CR133","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0021-9258(18)48388-3","volume":"267","author":"H Jiang","year":"1992","unstructured":"Jiang H, Colbran JL, Francis SH, Corbin JD (1992) Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J Biol Chem 267(2):1015\u20131019","journal-title":"J Biol Chem"},{"issue":"2","key":"1567_CR134","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/0333102418787336","volume":"39","author":"CE Christensen","year":"2019","unstructured":"Christensen CE, Amin FM, Younis S, Lindberg U, de Koning P, Petersen ET et al (2019) Sildenafil and calcitonin gene-related peptide dilate intradural arteries: a 3T MR angiography study in healthy volunteers. Cephalalgia 39(2):264\u2013273","journal-title":"Cephalalgia"},{"issue":"1","key":"1567_CR135","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s10194-018-0870-2","volume":"19","author":"S Younis","year":"2018","unstructured":"Younis S, Hougaard A, Christensen CE, Vestergaard MB, Petersen ET, Paulson OB et al (2018) Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0 T. J Headache Pain 19(1):44","journal-title":"J Headache Pain"},{"issue":"9","key":"1567_CR136","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1177\/03331024221080574","volume":"42","author":"L Kokoti","year":"2022","unstructured":"Kokoti L, Al-Karagholi MAM, Elbahi FA, Coskun H, Ghanizada H, Amin FM et al (2022) Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic. Cephalalgia 42(9):846\u2013858","journal-title":"Cephalalgia"},{"issue":"8","key":"1567_CR137","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/brain\/awab136","volume":"144","author":"MAM Al-Karagholi","year":"2021","unstructured":"Al-Karagholi MAM, Ghanizada H, Nielsen CAW, Hougaard A, Ashina M (2021) Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain 144(8):2322\u20132332","journal-title":"Brain"},{"issue":"5","key":"1567_CR138","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/bcpt.13787","volume":"131","author":"MA Al-Karagholi","year":"2022","unstructured":"Al-Karagholi MA, Hakbilen CC, Ashina M (2022) The role of high-conductance calcium-activated potassium channel in headache and migraine pathophysiology. Basic Clin Pharmacol Toxicol 131(5):347\u2013354","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"1567_CR139","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrn3770","volume":"15","author":"D Pietrobon","year":"2014","unstructured":"Pietrobon D, Moskowitz MA (2014) Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nat Rev Neurosci 15(6):379\u2013393","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"1567_CR140","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.3390\/ijms22115539","volume":"22","author":"M Waliszewska-Pros\u00f3\u0142","year":"2021","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Nowakowska-Kotas M, Chojdak-\u0141ukasiewicz J, Budrewicz S (2021) Migraine and sleep-an unexplained association? Int J Mol Sci 22(11):5539","journal-title":"Int J Mol Sci"},{"key":"1567_CR141","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cophys.2018.02.001","volume":"2","author":"D Pietrobon","year":"2018","unstructured":"Pietrobon D (2018) Ion channels in migraine disorders. Curr Opin Physio 2:98\u2013108","journal-title":"Curr Opin Physio"},{"issue":"2","key":"1567_CR142","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.neuron.2018.11.039","volume":"101","author":"P Royal","year":"2019","unstructured":"Royal P, Andres-Bilbe A, Prado P\u00c1, Verkest C, Wdziekonski B et al (2019) Migraine-associated TRESK mutations increase neuronal excitability through alternative translation initiation and inhibition of TREK. Neuron 101(2):232\u201345.e6","journal-title":"Neuron"},{"issue":"9","key":"1567_CR143","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.isci.2021.102961","volume":"24","author":"P\u00c1 Prado","year":"2021","unstructured":"Prado P\u00c1, Landra-Willm A, Verkest C, Ribera A, Chassot AA, Baron A et al (2021) TREK channel activation suppresses migraine pain phenotype. iScience. 24(9):102961","journal-title":"iScience."},{"issue":"12","key":"1567_CR144","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrneurol.2017.137","volume":"13","author":"M Ashina","year":"2017","unstructured":"Ashina M, Hansen JM, Dunga BO\u00e1, Olesen J (2017) Human models of migraine \u2014 short-term pain for long-term gain. Nat Rev Neurol 13(12):713\u2013724","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"1567_CR145","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s12031-014-0301-z","volume":"54","author":"M Koide","year":"2014","unstructured":"Koide M, Syed AU, Braas KM, May V, Wellman GC (2014) Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) dilates cerebellar arteries through activation of large-conductance Ca2 -activated (BK) and ATP-sensitive (KATP) K channels. J Mol Neurosci 54(3):443\u2013450","journal-title":"J Mol Neurosci"},{"issue":"10","key":"1567_CR146","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/0333102420949863","volume":"40","author":"MAM Al-Karagholi","year":"2020","unstructured":"Al-Karagholi MAM, Ghanizada H, Kokoti L, Paulsen JS, Hansen JM, Ashina M (2020) Effect of KATP channel blocker glibenclamide on levcromakalim-induced headache. Cephalalgia 40(10):1045\u20131054","journal-title":"Cephalalgia"},{"issue":"13","key":"1567_CR147","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1177\/03331024221114773","volume":"42","author":"A Citak","year":"2022","unstructured":"Citak A, Kilinc E, Torun IE, Ankarali S, Dagistan Y, Yoldas H (2022) The effects of certain TRP channels and voltage-gated KCNQ\/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system. Cephalalgia 42(13):1375\u20131386","journal-title":"Cephalalgia"},{"key":"1567_CR148","doi-asserted-by":"publisher","unstructured":"N\u2019Gouemo P (2014) BKCa channel dysfunction in neurological diseases. Front Physiol 5(373). https:\/\/doi.org\/10.3389\/fphys.2014.00373","DOI":"10.3389\/fphys.2014.00373"},{"issue":"4","key":"1567_CR149","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/head.12323","volume":"54","author":"J Yan","year":"2014","unstructured":"Yan J, Dussor G (2014) Ion channels and migraine. Headache 54(4):619\u2013639","journal-title":"Headache"},{"issue":"3","key":"1567_CR150","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF02110699","volume":"28","author":"GJ Kaczorowski","year":"1996","unstructured":"Kaczorowski GJ, Knaus HG, Leonard RJ, McManus OB, Garcia ML (1996) High-conductance calcium-activated potassium channels; Structure, pharmacology, and function. J Bioenerg Biomembr 28(3):255\u2013267","journal-title":"J Bioenerg Biomembr"},{"issue":"9","key":"1567_CR151","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.tins.2010.06.004","volume":"33","author":"US Lee","year":"2010","unstructured":"Lee US, Cui J (2010) BK channel activation: structural and functional insights. Trends Neurosci 33(9):415\u2013423","journal-title":"Trends Neurosci"},{"issue":"1","key":"1567_CR152","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.pain.2010.06.028","volume":"151","author":"S Akerman","year":"2010","unstructured":"Akerman S, Holland PR, Lasalandra MP, Goadsby PJ (2010) Inhibition of trigeminovascular dural nociceptive afferents by Ca2 -activated K (MaxiK\/BKCa) channel opening. Pain 151(1):128\u2013136","journal-title":"Pain"},{"issue":"3","key":"1567_CR153","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.pain.2013.12.005","volume":"155","author":"R Lu","year":"2014","unstructured":"Lu R, Lukowski R, Sausbier M, Zhang DD, Sisignano M, Schuh CD et al (2014) BKCa channels expressed in sensory neurons modulate inflammatory pain in mice. Pain 155(3):556\u2013565","journal-title":"Pain"},{"issue":"4","key":"1567_CR154","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40263-020-00706-8","volume":"34","author":"MAM Al-Karagholi","year":"2020","unstructured":"Al-Karagholi MAM, Gram C, Nielsen CAW, Ashina M (2020) Targeting BKCa channels in migraine: rationale and perspectives. CNS Drugs 34(4):325\u2013335","journal-title":"CNS Drugs"},{"issue":"11","key":"1567_CR155","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1177\/0333102420940681","volume":"40","author":"MAM Al-Karagholi","year":"2020","unstructured":"Al-Karagholi MAM, Ghanizada H, Nielsen CAW, Skandarioon C, Snellman J, Lopez Lopez C et al (2020) Opening of BKCa channels alters cerebral hemodynamic and causes headache in healthy volunteers. Cephalalgia 40(11):1145\u20131154","journal-title":"Cephalalgia"},{"issue":"10","key":"1567_CR156","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1097\/j.pain.0000000000002238","volume":"162","author":"MAM Al-Karagholi","year":"2021","unstructured":"Al-Karagholi MAM, Ghanizada H, Waldorff Nielsen CA, Skandarioon C, Snellman J, Lopez-Lopez C et al (2021) Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain 162(10):2512\u20132520","journal-title":"Pain"},{"issue":"4","key":"1567_CR157","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11940-019-0559-0","volume":"21","author":"JC Rau","year":"2019","unstructured":"Rau JC, Dodick DW (2019) Other preventive anti-migraine treatments: ACE inhibitors, ARBs, calcium channel blockers, serotonin antagonists, and NMDA receptor antagonists. Curr Treat Options Neurol 21(4):17","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"1567_CR158","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1526-4610.1983.hed2302070.x","volume":"23","author":"WK Amery","year":"1983","unstructured":"Amery WK (1983) Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 23(2):70\u201374","journal-title":"Headache"},{"issue":"3","key":"1567_CR159","doi-asserted-by":"publisher","first-page":"B139","DOI":"10.1016\/0002-9149(85)90622-8","volume":"55","author":"HJ Gelmers","year":"1985","unstructured":"Gelmers HJ (1985) Calcium-channel blockers in the treatment of migraine. Am J Cardiol 55(3):B139\u2013B143","journal-title":"Am J Cardiol"},{"issue":"4","key":"1567_CR160","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ana.20778","volume":"59","author":"C Ayata","year":"2006","unstructured":"Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59(4):652\u2013661","journal-title":"Ann Neurol"},{"issue":"8","key":"1567_CR161","doi-asserted-by":"publisher","first-page":"a003947","DOI":"10.1101\/cshperspect.a003947","volume":"3","author":"WA Catterall","year":"2011","unstructured":"Catterall WA (2011) Voltage-gated calcium channels. Cold Spring Harb Perspect Biol 3(8):a003947\u2013a003947","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"1567_CR162","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/pr.114.009654","volume":"67","author":"GW Zamponi","year":"2015","unstructured":"Zamponi GW, Striessnig J, Koschak A, Dolphin AC (2015) The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev 67(4):821\u2013870","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1567_CR163","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJM200107053450103","volume":"345","author":"A Ducros","year":"2001","unstructured":"Ducros A, Denier C, Joutel A, Cecillon M, Lescoat C, Vahedi K et al (2001) The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med 345(1):17\u201324","journal-title":"N Engl J Med"},{"issue":"3","key":"1567_CR164","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0092-8674(00)81373-2","volume":"87","author":"RA Ophoff","year":"1996","unstructured":"Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SMG et al (1996) Familial hemiplegic migraine and episodic ataxia Type-2 are caused by mutations in the Ca2 channel gene CACNL1A4. Cell 87(3):543\u2013552","journal-title":"Cell"},{"issue":"7","key":"1567_CR165","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.bbamem.2012.11.012","volume":"1828","author":"D Pietrobon","year":"2013","unstructured":"Pietrobon D (2013) Calcium channels and migraine. Biochim Biophys Acta 1828(7):1655\u20131665","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1567_CR166","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1523\/JNEUROSCI.19-05-01610.1999","volume":"19","author":"M Hans","year":"1999","unstructured":"Hans M, Luvisetto S, Williams ME, Spagnolo M, Urrutia A, Tottene A et al (1999) Functional consequences of mutations in the human \u03b11Acalcium channel subunit linked to familial hemiplegic migraine. J Neurosci 19(5):1610\u20131619","journal-title":"J Neurosci"},{"issue":"5","key":"1567_CR167","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.neuron.2009.01.027","volume":"61","author":"A Tottene","year":"2009","unstructured":"Tottene A, Conti R, Fabbro A, Vecchia D, Shapovalova M, Santello M et al (2009) Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in CaV2.1 knockin migraine mice. Neuron 61(5):762\u2013773","journal-title":"Neuron"},{"issue":"5","key":"1567_CR168","doi-asserted-by":"publisher","first-page":"RC213","DOI":"10.1523\/JNEUROSCI.22-05-j0002.2002","volume":"22","author":"YE Knight","year":"2002","unstructured":"Knight YE, Bartsch T, Kaube H, Goadsby PJ (2002) P\/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 22(5):RC213\u2013RC213","journal-title":"J Neurosci"},{"issue":"4","key":"1567_CR169","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1177\/0271678X17725673","volume":"39","author":"KY Chan","year":"2019","unstructured":"Chan KY, Labastida-Ram\u00edrez A, Ram\u00edrez-Rosas MB, Labruijere S, Garrelds IM, Danser AH et al (2019) Trigeminovascular calcitonin gene-related peptide function in Cacna1a R192Q-mutated knock-in mice. J Cereb Blood Flow Metab 39(4):718\u2013729","journal-title":"J Cereb Blood Flow Metab"},{"issue":"52","key":"1567_CR170","doi-asserted-by":"publisher","first-page":"36453","DOI":"10.1074\/jbc.M109.075523","volume":"284","author":"ZZ Wu","year":"2009","unstructured":"Wu ZZ, Li DP, Chen SR, Pan HL (2009) Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel \u03b2 subunit. J Biol Chem 284(52):36453\u201336461","journal-title":"J Biol Chem"},{"issue":"1","key":"1567_CR171","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12311-018-0917-6","volume":"17","author":"PDH Pastor","year":"2018","unstructured":"Pastor PDH, Du X, Fazal S, Davies AN, Gomez CM (2018) Targeting the CACNA1A IRES as a treatment for spinocerebellar ataxia Type 6. The Cerebellum 17(1):72\u201377","journal-title":"The Cerebellum"},{"issue":"1","key":"1567_CR172","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.biochem.75.103004.142819","volume":"76","author":"K Venkatachalam","year":"2007","unstructured":"Venkatachalam K, Montell C (2007) TRP channels. Annu Rev Biochem 76(1):387\u2013417","journal-title":"Annu Rev Biochem"},{"issue":"6","key":"1567_CR173","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/35077544","volume":"2","author":"DE Clapham","year":"2001","unstructured":"Clapham DE, Runnels LW, Str\u00fcbing C (2001) The TRP ion channel family. Nat Rev Neurosci 2(6):387\u2013396","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"1567_CR174","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1021\/cn500083e","volume":"5","author":"G Dussor","year":"2014","unstructured":"Dussor G, Yan J, Xie JY, Ossipov MH, Dodick DW, Porreca F (2014) Targeting TRP channels for novel migraine therapeutics. ACS Chem Neurosci 5(11):1085\u20131096","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"1567_CR175","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/sj.bjp.0705486","volume":"140","author":"S Akerman","year":"2003","unstructured":"Akerman S, Kaube H, Goadsby PJ (2003) Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br J Pharmacol 140(4):718\u2013724","journal-title":"Br J Pharmacol"},{"issue":"16","key":"1567_CR176","doi-asserted-by":"publisher","first-page":"16377","DOI":"10.1074\/jbc.M310891200","volume":"279","author":"LJ K\u00e1rai","year":"2004","unstructured":"K\u00e1rai LJ, Russell JT, Iadarola MJ, Ol\u00e1h Z (2004) Vanilloid receptor 1 regulates multiple calcium compartments and contributes to Ca2 -induced Ca2 release in sensory neurons. J Biol Chem 279(16):16377\u201316387","journal-title":"J Biol Chem"},{"issue":"5","key":"1567_CR177","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1526-4610.2011.02053.x","volume":"52","author":"MS Evans","year":"2012","unstructured":"Evans MS, Cheng X, Jeffry JA, Disney KE, Premkumar LS (2012) Sumatriptan inhibits TRPV1 channels in trigeminal neurons. Headache 52(5):773\u2013784","journal-title":"Headache"},{"issue":"13","key":"1567_CR178","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1073\/pnas.1337252100","volume":"100","author":"M Numazaki","year":"2003","unstructured":"Numazaki M, Tominaga T, Takeuchi K, Murayama N, Toyooka H, Tominaga M (2003) Structural determinant of TRPV1 desensitization interacts with calmodulin. Proc Natl Acad Sci 100(13):8002\u20138006","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"1567_CR179","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1046\/j.1468-2982.2000.00088.x","volume":"20","author":"S Diamond","year":"2000","unstructured":"Diamond S, Freitag F, Phillips SB, Bernstein JE, Saper JR (2000) Intranasal civamide for the acute treatment of migraine headache. Cephalalgia 20(6):597\u2013602","journal-title":"Cephalalgia"},{"issue":"6","key":"1567_CR180","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/bja\/aeg572","volume":"90","author":"BM Fusco","year":"2003","unstructured":"Fusco BM, Barzoi G, Agr\u00f2 F (2003) Repeated intranasal capsaicin applications to treat chronic migraine. Br J Anaesth 90(6):812","journal-title":"Br J Anaesth"},{"issue":"2","key":"1567_CR181","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/brain\/awr272","volume":"135","author":"R Nassini","year":"2012","unstructured":"Nassini R, Materazzi S, Vriens J, Prenen J, Benemei S, De Siena G et al (2012) The \u201cheadache tree\u201d via umbellulone and TRPA1 activates the trigeminovascular system. Brain 135(2):376\u2013390","journal-title":"Brain"},{"issue":"12","key":"1567_CR182","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1016\/j.pain.2013.08.002","volume":"154","author":"S Materazzi","year":"2013","unstructured":"Materazzi S, Benemei S, Fusi C, Gualdani R, De Siena G, Vastani N et al (2013) Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. Pain 154(12):2750\u20132758","journal-title":"Pain"},{"issue":"1","key":"1567_CR183","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12264-020-00569-5","volume":"37","author":"M Shibata","year":"2021","unstructured":"Shibata M, Tang C (2021) Implications of transient receptor potential cation channels in migraine pathophysiology. Neurosci Bull 37(1):103\u2013116","journal-title":"Neurosci Bull"},{"issue":"768","key":"1567_CR184","doi-asserted-by":"publisher","first-page":"136380","DOI":"10.1016\/j.neulet.2021.136380","volume":"18","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, De Logu F, Geppetti P, De Cesaris F (2022) The role of TRP ion channels in migraine and headache. Neurosci Lett 18(768):136380","journal-title":"Neurosci Lett"},{"issue":"48","key":"1567_CR185","doi-asserted-by":"publisher","first-page":"13251","DOI":"10.1523\/JNEUROSCI.2135-07.2007","volume":"27","author":"H Cadiou","year":"2007","unstructured":"Cadiou H, Studer M, Jones NG, Smith ESJ, Ballard A, McMahon SB et al (2007) Modulation of acid-sensing ion channel activity by nitric oxide. J Neurosci 27(48):13251\u201313260","journal-title":"J Neurosci"},{"issue":"11","key":"1567_CR186","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/bph.14990","volume":"177","author":"CM Holton","year":"2020","unstructured":"Holton CM, Strother LC, Dripps I, Pradhan AA, Goadsby PJ, Holland PR (2020) Acid-sensing ion channel 3 blockade inhibits durovascular and nitric oxide-mediated trigeminal pain. Br J Pharmacol 177(11):2478\u20132486","journal-title":"Br J Pharmacol"},{"key":"1567_CR187","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neuropharm.2014.12.015","volume":"94","author":"G Dussor","year":"2015","unstructured":"Dussor G (2015) ASICs as therapeutic targets for migraine. Neuropharmacology 94:64\u201371","journal-title":"Neuropharmacology"},{"issue":"2","key":"1567_CR188","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s13311-018-0619-2","volume":"15","author":"N Karsan","year":"2018","unstructured":"Karsan N, Gonzales EB, Dussor G (2018) Targeted acid-sensing ion channel therapies for migraine. Neurotherapeutics 15(2):402\u2013414","journal-title":"Neurotherapeutics"},{"issue":"15","key":"1567_CR189","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3390\/cells11152406","volume":"11","author":"A Clement","year":"2022","unstructured":"Clement A, Guo S, Jansen-Olesen I, Christensen SL (2022) ATP-sensitive potassium channels in migraine: translational findings and therapeutic potential. Cells 11(15):2406","journal-title":"Cells"},{"issue":"1","key":"1567_CR190","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1468-1331.1994.tb00053.x","volume":"1","author":"LL Thomsen","year":"1994","unstructured":"Thomsen LL, Kruuse C, Iversen HK, Olesen J (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1(1):73\u201380","journal-title":"Eur J Neurol"},{"issue":"9","key":"1567_CR191","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1093\/brain\/awz199","volume":"142","author":"MAM Al-Karagholi","year":"2019","unstructured":"Al-Karagholi MAM, Hansen JM, Guo S, Olesen J, Ashina M (2019) Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain 142(9):2644\u20132654","journal-title":"Brain"},{"issue":"4","key":"1567_CR192","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00198-007-0490-1","volume":"19","author":"CH Chesnut 3rd","year":"2008","unstructured":"Chesnut CH 3rd, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 19(4):479\u2013491","journal-title":"Osteoporos Int"},{"issue":"3","key":"1567_CR193","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1526-4610.1988.hed2803196.x","volume":"28","author":"G Micieli","year":"1988","unstructured":"Micieli G, Cavallini A, Martignoni E, Covelli V, Facchinetti F, Nappi G (1988) Effectiveness of salmon calcitonin nasal spray preparation in migraine treatment. Headache 28(3):196\u2013200","journal-title":"Headache"},{"issue":"6","key":"1567_CR194","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/1440-1681.12915","volume":"45","author":"E Kilinc","year":"2018","unstructured":"Kilinc E, Dagistan Y, Kukner A, Yilmaz B, Agus S, Soyler G et al (2018) Salmon calcitonin ameliorates migraine pain through modulation of CGRP release and dural mast cell degranulation in rats. Clin Exp Pharmacol Physiol 45(6):536\u2013546","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1567_CR195","doi-asserted-by":"publisher","first-page":"101109","DOI":"10.1016\/j.molmet.2020.101109","volume":"46","author":"N Sonne","year":"2021","unstructured":"Sonne N, Karsdal MA, Henriksen K (2021) Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases. Mol Metab 46:101109. https:\/\/doi.org\/10.1016\/j.molmet.2020.101109","journal-title":"Mol Metab"},{"issue":"1","key":"1567_CR196","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0333102416636097","volume":"37","author":"M Lindblad","year":"2017","unstructured":"Lindblad M, Hougaard A, Amin FM, Ashina M (2017) Can migraine aura be provoked experimentally? A systematic review of potential methods for the provocation of migraine aura. Cephalalgia 37(1):74\u201388","journal-title":"Cephalalgia"},{"issue":"2","key":"1567_CR197","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1055\/s-2004-835370","volume":"4","author":"BMY Cheung","year":"2004","unstructured":"Cheung BMY, Li CYY, Wong LYF (2004) Adrenomedullin: its role in the cardiovascular system. Semin Vasc Med 4(2):129\u2013134","journal-title":"Semin Vasc Med"},{"key":"1567_CR198","doi-asserted-by":"publisher","first-page":"549038","DOI":"10.3389\/fneur.2020.549038","volume":"11","author":"L Al-Hassany","year":"2020","unstructured":"Al-Hassany L, Haas J, Piccininni M, Kurth T, Maassen Van Den Brink A, Rohmann JL (2020) Giving researchers a headache - sex and gender differences in migraine. Front Neurol 11:549038","journal-title":"Front Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01567-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01567-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01567-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T17:29:59Z","timestamp":1702661399000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01567-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":198,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01567-4","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]},"assertion":[{"value":"31 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Linda Al-Hassany, Deirdre M. Boucherie, Hannah Creeney, Ruben W.A.van Drie, Fatemeh Farham, Silvia Favaretto, Grangeon Lou, Hannah Lyons, Karol Marschollek, Dilara Onan, Umberto Pensato, Emily Stanyer, Marta Waliszewska-Pros\u00f3\u0142, Hui Zhou Chen declare no conflict of interest. C\u00e9dric Gollion reports speaker fees from Teva, Novartis, Lundbeck and Lilly. Wietse Wiels declares to have received an FWO Vlaanderen Fundamental Research scholarship. Faisal Mohammad Amin has received Honoraria or personal fees from Pfizer, Teva, Novartis, Lundbeck and Eli Lilly for lecturing or participating in advisory boards; is principal investigator for phase IV trials sponsored by Novartis and by Teva; serves as president of Danish Headache Society and board member of the European Headache Federation; serves as associate editor for Acta Neurol Scand, Front Neurol, Front Res Pain, and Headache Medicine; serves as junior associate editor for Cephalalgia and Cephalalgia Reports; member of the editorial board of J Headache Pain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}